David R. Martinez

56. Snouwaert J, Jania L, Nguyen T, Martinez, D.R., Schäfer A, Catanzaro, N, Gully K, Baric R.S., Heise M, Ferris M, Anderson E, Pressey K, Dillard J, Taft-Benz S, Baxter V, Ting J, Koller B.H., Human ACE2 expression, a major tropism determinant for SARS-CoV-2, is regulated by upstream and intragenic elements. PLoS Pathogens. February 22, 2023. https://doi.org/10.1371/journal.ppat.1011168

55. Zhou P, Song G, Liu H, Yuan M, He W, Beutler N, Zhu X, Tse LV, Martinez, D.R., Schäfer A, Anzanello F, Yong P, Peng L, Dueker K, Musharrafieh R, Callaghan S, Capozzola R, Limbo O, Parren M, Garcia E, Rawlings S, Smith D, Nemazee D, Jardine J, Safonova Y, Briney B, Rogers T, Wilson I, Baric R.S., Gralinski L, Burton D, Andrabi R. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity. February 16, 2023. https://doi.org/10.1016/j.immuni.2023.02.005

54. Dagotto G, Ventura J, Martinez D.R., Anioke T, Chung B, Siamatu M, Barrett J, Miller J, Schaefer A, Yu J, Tostanoski L, Wagh K, Baric R.S., Korber B, Barouch D.H. Immunogenicity and protective efficacy of a rhesus adenoviral vaccine targeting conserved COVID-19 replication transcription complex. Nature NPJ Vaccines. October 27, 2022. https://doi.org/10.1038/s41541-022-00553-2

53. Li D, Martinez D.R., Schaefer A., Chen H, Barr M, Sutherland L, Lee E, Parks, R, Mielke D, Edwards W, Newman A, Bock K, Minai M, Nagata B, Gagne M, Douek D, DeMarco T, Denny T, Oguin T, Brown A, Rountree W, Wang Y, Mansouri K, Edwards R, Ferrari G, Sempowski G, Eaton A, Tang J, Cain D, Santra S, Pardi N, Weissman D, Tomai M, Fox C, Moore I, Andersen H, Lewis M, Golding H, Seder R, Khurana S, Baric R.S., Montefiori D, Saunders K, Haynes B.F. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine. Nature Communications. October 23, 2022. https://www.nature.com/articles/s41467-022-33985-4

52. C. Chen, Saville J, Marti M, Schaefer A, Cheng M, Mannar D, Zhu X, Berezuk A, Banerjee A, Sobolewski M, Kim A, Treat B, Castanha P, Enick N, McCormick K, Liu X, Adams C, Hines M, Sun Z, Chen W, Jacobs, J, Barratt-Boyes S, Mellors J, Baric R, Bahar I, Dimitrov D,# Subramaniam S,# Martinez D.R. # Li W.# Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. iScience. July 20, 2022. https://doi.org/10.1016/j.isci.2022.104798

# Co-senior and co-corresponding author.

51. Schäfer A, Leist S, Gralinski L, Martinez D.R., Winkler E, Okuda K, Hawkins P, Gully K, Graham R, Scobey T, Bell T, Hock P, Shaw G, Loome J, Madden E, Anderson E, Baxter V, Taft-Benz S, Zweigart M, May S, Dong S, Clark M, Miller D, Lynch R, Heise M, Tisch R, Boucher R, Pardo Manuel de Villena F, Montgomery S, Diamond M, Ferris M, Baric R.S. A Multitrait Locus Regulates Sarbecovirus Pathogenesis. mBio. July 12, 2022. DOI:https://doi.org/10.1128/mbio.01454-22

50. He W, Musharrafieh R, Song G, Dueker K, Tse L.V., Martinez D.R., Schaefer A, Callaghan S, Yong P, Beutler N, Torres J, Volk R, Zhou P, Yuan M, Liu H, Anzanello F, Capozzola T, Parren M, Garcia E, Rawlings S, Smith D, Wilson I, Safonova Y, Ward A, Rogers T, Baric R.S., Gralinski L, Burton D, Andrabi R. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses. Nature Immunology. June 2, 2022. https://doi.org/10.1038/s41590-022-01222-1

Featured on the cover of the June 6th 2022 Issue.

49. Schaefer A++, Martinez D.R. ++, Won JJ, Meganck R., Moreira, F., Brown A., Gully K, Zweigart M, Conrad W, May S, Dong S, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett K, Bleier B, Bannister R, Feng J, Bilello J, Cihlar T, Mackman R, Montgomery S, Baric, R.S, Sheahan T.P. Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Science Translational Medicine. March 22, 2022. DOI: 10.1126/scitranslmed.abm3410 ++Co-first author.

48. Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N, He X, Liu J, McMahan K, Martinot A, Martinez D.R., Giffin T, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole A, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis M, Boon A, Baric R.S, Mueller S, Petsch B, Barouch D.H. Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine. Nature. November 18, 2021. https://doi.org/10.1038/s41586-021-04231-6

47. Martinez D.R.++, Schäfer A++, Gobeil S++, Li D++, De la Cruz G, Parks R, Lu X, Barr M, Stalls C, Janowska K, Beadouin E, Manne K, Mansouri K, Edwards R, Cronin K, Yount B, Anasti K, Montgomery S, Tang J, Golding H, Shen S, Zhou T, Kwong P, Graham B.S, Mascola J, Montefiori D, Alam M, Sempowski GD, Khurana S, Wiehe K, Saunders K, Acharya P, Haynes B.F, Baric R.S. A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine. November 2, 2021. DOI: 10.1126/scitranslmed.abj7125 ++Co-first author.

Featured on the cover of the January 26th 2022 Issue.

46. Collier A, Yu J, McMahan K, Liu J, Chandrashekar A, Maron J, Atyeo C, Martinez D.R., Ansel J, Aguayo R, Rowe M, Jacol-Dolan C, Sellers D, Barrett J, Ahmad K, Anioke T, VanWyk H, Gardner S, Powers O, Bondzie E, Wan H, Baric R.S., Alter G, Hacker M, Barouch DH. Differential Kinetics of Immune Responses Elicited by COVID-19 Vaccines. NEJM. October 15, 2021. doi: 10.1056/NEJMc2115596.

45. Walls A, Miranda M, Schaefer A, Pham M, Greaney A, Arunachalam P, Navarro M, Tortorici M, Rogers K, O’Connor M, Shirreff L, Ferrell D, Bowen J, Brunettte N, Kepl E, Zepeda S, Starr T, Hsieh C, Fiala B, Wrenn S, Pettie D, Sydeman C, Sprouse K, Johnson M, Blackstone A, Racichandra R, Ogohara C, Carter L, Tilles S, Rappouli R, Leist S, Martinez D.R., Clark M, Tish R, O’Hagan D, Van Der Voorhis W, Corti D, McLellan J, Kleanthous H, Sheahan T, Smith K Fuller D, Villinger F, Bloom J, Pulendran B, Baric R, King N, Veesler D. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell. September 15, 2021. DOI:https://doi.org/10.1016/j.cell.2021.09.015

44. Tostanoski L++, Gralinski L++, Martinez D.R. ++, Schaefer A++, Mahrokhian S, Li S, Nampanya F, Wan H, Yu J, Chang A, Liu J, McMahan K, Ventura J, Dinnon K, Leist S, Baric R.S., Barouch DH., Protective efficacy of rhesus adenovirus COVID-19 vaccines against mouse-adapted SARS-CoV-2. JVI. September 15, 2021. DOI: 10.1128/JVI.00974-21 ++ Co-first author

43. Markmann A, Giallourou N, Bhowmilk D, Hou Y, Lerner A, Martinez D.R., Premkumar L, Root H, van Duin H, Napravnik S, Graham S, Guerra Q, Raut R, Petropulous C, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R.S, de Silva A, Margolis D, Bartlet L. Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals. mSphere. August 25, 2021. DOI: 10.1128/mSphere.00275-21

42. Martinez D.R. # ++, Schäfer A ++, Leist S, Li D, Gully K, Yount B, Feng J, Bunyan E, Porter D, Cihlar T, Montgomery S, Haynes B.F., Baric R.S., Nussenzweig M.C., Sheahan T #. Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice. Cell Reports. July 13, 2021. DOI: https://doi.org/10.1016/j.celrep.2021.109450 # Corresponding author ++ Co-first author

41. Wang, L., Zhou T, Zhang Y, Yan ES, Schramm C, Shi W, Pegu A, Oloniniyi O, Henry A, Darko S, Narpala S, Hatcher C, Martinez, D.R., Tsybovsky Y, Phung E, Corbett KS., Davis R, DiPiazza A, Gordon I, Helmold S, Hermanus T, Kgagudi P, Laboune F, Leung K, Liu T, Mason R, Nazzari A, Novik L, O’connel S, O’Dell S, Olia A, Schidt S, Stephens T, Stringham C, Talana C, Teng I, Wagner D, Widge A, Zhang B, Roederer M, Ledgerwood J, Ruckwardt T, GAudinski M, Moore P, Doria-Rose N, Baric RS, Graham BS, McDermott A, Douek D, Kwong P, Mascola J, Sullivan N, Misasi J. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. July 1, 2021. DOI: 10.1126/science.abh1766

40. Yu J, Tostanoski L, Mercado N, McMahan K, Liu J, Jacob-Dolan C, Chadrashekar A, Ateyo C, Martinez D.R., Anioke T, Bndzie E, Chang A, Gardner S, Giffin V, Hope D, Nampanya F, Nkolola J, Patel S, Sanborn O, Sellers D, Wan H, Hayes T, Bauer K, Pessaint L, Valentin D, Flichbaugh Z, Brown R, Cook A, Bueno-Wilkerson D, Teow E, Andersen H, Lewis M, Martinot A, Baric R.S., Alter G, Wegmann F, Zahn R, Schuitemaker H, Barouch D.H. Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. June 23, 2021. https://doi.org/10.1038/s41586-021-03732-8 (2021).

39. Martinez D.R.#, Schäfer A, Leist S, De la Cruz G, West A, Atochina-Vasserman E, Lindesmith L, Pardi N, Parks R, Barr M, Li D, Yount B, Saunders K, Weissman D, Haynes B.F., Montgomery S, Baric R.S., #. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. Science. June 22, 2021. DOI: 10.1126/science.abi4506 # Corresponding author.

38. Li D++, Edwards R++, Manne K++, Martinez D.R.++, Schäfer A++, Alam M, Wiehe K, Lu X, Parks R, Sutherland L, Oguin T, McDanal C, Perez L, Mansouri K, Gobeil S, Janowska K, Stalls V, Kopp M, Cai F, Lee E, Foulger A, Hernandez G, Sanzone A, Tilahun K, Jiang C, Tse L, Bock K, Minai M, Nagata B, Cronin K, Gee-Lai V, Deyton M, Barr M, Von Holle T, Macintyre A, Stover E, Feldman J, Hauser B, Caradonna T, Scobey T, Rountree W, Wang Y, Moody M, Cain D, DeMarco C, Denny T, Woods C, Petzold E, Schmidt A, Teng I, Zhou T, Kwong P, Mascola J, Graham B, Moore I, Seder R, Andersen H, Lewis M, Montefiori D, Sempowski G, Baric R.S, Acharya P, Haynes B.F, Saunders K. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. June 18, 2021. DOI:https://doi.org/10.1016/j.cell.2021.06.021 ++ Co-first author

37. Alter G, Yu J, Liu J, Chandrashekar A, Borducchi E, Tostanoski L, McMahan K, Jacob-Dolan C, Martinez D.R., Chang A, Anioke T, Lifton M, Nkolola J, Stephenson K, Atyeo C, Shin S, Fields P, Kaplan I, Robins H, Amanat F, Krammer F, Baric R.S, Le Gars M, Sadoff J, de Groot A, Heerwegh D, Struyf F, Douoguih M, van Hoof J, Schuitemaker H, Barouch D.H. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Nature. June 9, 2021. https://doi.org/10.1038/s41586-021- 03681-2 (2021).

36. Shiakolas A, Kramer K, Wrapp D, Richardson S, Schäfer A, Wall S, Wang N, Janowska K, Pilewski K, Venkat R, Parks R, Manamela N, Raju N, Friedman Fechter E, Holt C, Suryadevara N, Chen R, Martinez D.R., Nargi R, Sutton R, Ledgerwood J, Graham B.S, Diamond M.S, Haynes B.F., Acharya P, Carnahan R, Crowe, Jr. J, Baric R.S., Morris L, McLellan J.S., Georgiev I. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Reports Medicine. May 22, 2021. https://doi.org/10.1016/j.xcrm.2021.100313

35. Saunders KO, Lee E, Parks R, Martinez D.R., Li D, Chen H, Edwards R.J, Gobeil S, Barr M, Mansouri K, Alam M, Sutherland L, Cai F, Sanzone A, Berry M, Manne K,

Bock K, Minai M, Nagata B, Kapingidza A, Azoitei M, Tse LV, Scobey T, Spreng R, Rountree W, DeMarco T, Denny T, Woods C, Petzold E, Tang J, Oguin III T, Sempowski G, Gagne M, Douek D, Tomai M, Fox C, Seder R, Wiehe K, Weissman D, Pardi N, Golding H, Khurana S, Acharya P, Andersen H, Lewis M, Moore I, Montefiori D, Baric, R.S., Haynes B.F.Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. May 10, 2021. https://doi.org/10.1038/s41586-021-03594-0

34. Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec T, Wiethoff C, Blackbourne JL, Heinz B, Foster D, Higgs R, Balasubramaniam D, Wang L, Zhang Y, Yang ES, Bidshahri R, Kraft L, Hwang Y, Zentelis S, Jepson K, Goya R, Smith M, Collins D, Hinshaw S, Tycho S, Pellacani D, Xiang P, Muthuraman K, Sobhanifar S, Piper M, Triana F, Hendle J, Pustilnik A, Adams A, Berens S, Baric RS, Martinez D.R., Cross RW, Geisbert TW, Borisevich V, Abiona O, Belli H, de Vries M, Mohamed A, Dittmann M, Samanovic M, Mulligan MJ, Goldsmith JA, Hsieh CL, Johnson NV, Wrapp D, McLellan JS, Barnhart V, Graham BS, Mascola JR, Hansen C, and Falconer E. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates. Science Translational Medicine. April 5, 2021. DOI: 10.1126/scitranslmed.abf1906

• Bamlanivimab tested in Phase I, Phase II, and Phase III clinical trials by Eli Lilly. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2020.

33. Yu J, Li Z, He X, Gebre M, Bondzie E, Wan H, Jacob-Dolan C, Martinez D.R., Nkolola J, Baric R.S., Barouch DH. Deletion of the SARS-CoV-2 Spike Cytoplasmic Tail Increases Infectivity in Pseudovirus Neutralization Assays. Journal of Virology. March 16, 2021. doi: 10.1128/JVI.00044-21.

32. Dagotto G, Mercado N, Martinez D.R., Hou Y, Nkolola J, Carnahan RH, Crowe Jr JE, Baric RS, Barouch DH. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. Journal of Virology. January 20, 2021. doi: 10.1128/JVI.02370-20

31. Schäfer A, Muecksch F, Lorenzi J, Leist SR, Cipolla M, Bournazos S, Schmidt F, Maison R, Gazumyan A, Martinez D. R., Baric RS, Robbiani D, Hatziioannou T, Ravetch J, Bieniasz P, Bowen R, Nussenzweig MC, Sheahan TP. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine. November 19, 2020. doi: 10.1084/jem.20201993

30. Li W++, Chen C++, Drelich A++, Martinez, D.R., ++, Gralinski LE++, Sun Z++, Schäfer A++, Kulkarni SS++, Liu X, Leist SR, Zhelev DV, Zhang L, Kim Y, Peterson E, Conard A, Mellors J, Tseng CTK, Falzarano D, Baric RS, and Dimitrov DS. Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection. PNAS. November 2, 2020. doi.org/10.1073/pnas.2010197117 ++ Co-first author

29. Martinez, D.R. #, Yount, B, Nivarhi, U, Munt J, Delacruz M, Whitehead S, Durbin A, De Silva A, Baric, RS#. Antigenic variation of the dengue virus 2 genotypes impacts the neutralization activity of human antibodies in vaccinees. Cell Reports. October 6, 2020. https://doi.org/10.1016/j.celrep.2020.108226 # Corresponding author.

28. Anderson EJ, Rouphael N, Widge A, Jackson L, Roberts P, Makhene M, Chappell J, Denison M, Stevens L, Pruijssers A, McDermott A, Flach B, Lin B, Doria-Rose N, O’Dell N, Schidth S, Corbett K, Swanson P, Padilla M, Neuzil K, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara V, Floyd K, Suthar M, Martinez, D.R., Baric RS, Buchanan W, Luke C, Phadke V, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH, for the mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. NEJM. September 29, 2020. DOI: 10.1056/NEJMoa2028436.

• mRNA 1273 vaccine tested in Phase I, Phase II, and Phase III clinical trials by Moderna. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2020. Fully approved by the FDA in 2022.

27. Li W ++, Schaefer A++, Kulkarni SS++, Liu X++, Martinez, D.R.++, Chen C, Sun Z, Leist SR, Drelich A, Zhang L, Ura ML, Berezuk A, Chittori S, Leopold K, Mannar D, Srivastava S, Zhu X, Peterson EC, Tseng CT, Mellors JW, Falzarano D, Subramaniam S, Baric RS, Dimitrov DS. High potency of a bivalent human VH domain in SARS-CoV-2 animal models. Cell. September 4, 2020. doi:https://doi.org/10.1016/j.cell.2020.09.007 ++ Co-first author

26. Dinnon III, K, Leist SR, Schäfer A, Edwards CE, Martinez, DR, Montgomery SA, West A, Yount Jr BL, Hou YJ, Adams LE, Gully KL, Brown AJ, Huang E, Bryant MD, Choong CI,

Glenn JS, Gralinski LE, Sheahan TP, Baric. RS. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. August 27, 2020. https://doi.org/10.1038/s41586-020-2708-8

25. Corbett KS, Edwards D, Leist SR, Abiona O, Boyoglu-Barnum S, Gillespie R, Himansu S, Schaefer A, Ziwawo C, DiPiazza A, Dinnon K, Elbashir S, Shaw C, Woods A, Fritch E, Martinez, D.R., Bock K, Mahnaz M, Nagata B, Hutchinson G, Wu K, Henry C, Bahi K, Garcia-Dominguez D, Ma L, Renzi I, Kong WP, Schmidt S, Wang L, Zhang Y, Phung E, Chang L, Loomis R, Altaras N, Nayayanan E, Metkar M, Presnyak V, Liu C, Louder M, Shi W, Leung K, Yang E, West A, Gully K, Stevens L, Wang N, Wrapp D, Doria-Rose N, Stewart-Jones G, Bennet H, Alvarado G, Nason M, Ruckwardt T, McLelland J, Denison M, Chappell J, Moore I, Morabito K, Mascola J, Baric RS, Carfi A, Graham B. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. August 5, 2020. doi: 10.1038/s41586-020-2622-0.

• mRNA 1273 vaccine tested in Phase I, Phase II, and Phase III clinical trials by Moderna. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2020. Fully approved by the FDA in 2022.

24. Mercado NB++, Zahn R++, Wegmann F++, Loos C++, Chandrashekar A++, Yu J++, Liu J++, Peter L++, McMahan K++, Tostanoski L++, He X++, Martinez D.R.++, Rutten L, Bos R, van Manen D, Vellinga J, Custers J, Langedijk J, Kwaks T, Bakkers MJG, Zuijdgeest D, Rosendahl Huber SK, Atyeo C, Fischinger S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS, Hoffman E, Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield L, Nampanya F, Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Van Ry A, Blade K, Strasbaugh A, Cabus M, Brown R, Cook A, Zouantchangadou S, Teow E, Andersen H, Lewis MG, Cai Y, Chen B, Schmidt AG, Reeves RK, Baric RS, Lauffenburger DA, Alter G, Stoffels P, Mammen M, Van Hoof J, Schuitemaker H, Barouch DH. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. July 30, 2020. https://doi.org/10.1038/s41586-020-2607-z ++ Co-first author

• Ad26 vaccine tested in Phase I, Phase II, and Phase III clinical trials by Johnson and Johnson. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2021.

23. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B, O’Connell S, Bock KW, Minai M, Nagata BM, Anderson H, Martinez D.R., Noe AT, Douek N, Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin BC, Louder MK, O’Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JP, Pessaint L, Van Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell T, Cook A, Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona O, Wang L, Pegu A, Yang ES, Leung K, Zhou T, Teng I, Widge A, Gordon I, Novik L, Gillespie R, Loomis R, Moliva J, Stewart-Jones G, Himansu S, Kong WP, Nason M, Morabito K, Ruckwardt T, Ledgerwood J, Gaudinski M, Kwong PD, Mascola JR, Carfi A, Lewis MG, Baric RS, McDermott A, Moore IN, Sullivan NJ, Roederer M, Seder RA, Graham BS. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. NEJM. July 28, 2020. DOI: 10.1056/NEJMoa2024671

• mRNA 1273 vaccine tested in Phase I, Phase II, and Phase III clinical trials by Moderna. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2020. Fully approved by the FDA in 2022.

22. Pruijssers A, George A, Schaefer A, Leist S, Gralinski L, Dinnon K, Yount B, Agostini M, Stevens L, Chappell J, Lu X, Hughes T, Gully K, Martinez, D.R., Brown A, Graham R, Perry J, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng J, Bilello J, Porter D, Cihlar T, Baric RS, Denison MR, Sheahan TP. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Reports. July 21, 2020. doi: 10.1016/j.celrep.2020.107940.

• Small molecule Remdesivir tested in Phase I, Phase II, and Phase III clinical trials by Gilead Inc. Issued Emergency Use Authorization (EUA) by the U.S. FDA in 2020. Fully approved by the FDA in 2020.

21. Zost SJ, Gilchuk P, Case JB, Binshtein E, Chen RE, Nkolola JP, Schäfer A, Reidy JX, Trivette A, Nargi RS, Sutton RE, Suryadevara N, Martinez, D.R., Williamson LE, Chen EC, Jones T, Day S, Myers L, Hassan AO, Kafai N, Winkler ES, Fox J, Shrihari S, Mueller B, Meiler J, Chandrashekar A, Mercado NB, Steinhardt J, Ren K, Loo YM, Kallewaard N, McCune BT, Keeler SP, Holtzman M, Barouch DH, Gralinski L, Baric RS, Thackray L, Diamond MS, Carnahan RH, Crowe JE Jr. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. July 15, 2020. https://doi.org/10.1038/s41586-020-2548-6

• mAbs (Evusheld) licensed to AstraZeneca and tested in Phase I, II, and III clinical trials. Evusheld issued Emergency Use Authorization (EUA) by the U.S. FDA in 2021.

20. Zost SJ, Gilchuk P, Chen R, Case B, Reidy J, Trivette A, Nargi R, Sutton R, Suryadevara N, Chen E, Binshtein E, Shrihari S, Ostrowski M, Chu H, Didier J, McRenaris K, Jones T, Day S, Myers L, Eun-Hyung Lee, Nguyen D, Sanz I, Martinez, D.R., Rothlauf P, Bloyet L, Whelan S, Baric RS, Thackray L, Diamond MS, Carnahan R, Crowe J. Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. Nature Medicine. July 10, 2020. https://doi.org/10.1038/s41591-020-0998-x

• mAbs (Evusheld) licensed to AstraZeneca and tested in Phase I, II, and III clinical trials. Evusheld issued Emergency Use Authorization (EUA) by the U.S. FDA in 2021.

19. Sun Z ++, Chen C++, Wei Li ++, Martinez, D.R., ++, Drelich A ++, Baek DS, Liu X, Mellors JW, Tseng CT, Baric RS, Dimitrov DS. Potent neutralization of SARS-CoV-2 by human antibody heavy-chain variable domains isolated from a large library with a new stable scaffold. mAbs. June 16, 2020. https://doi.org/10.1080/19420862.2020.1778435 ++ Co-first author

18. Lakshmanane P, Segovia B, Jadi R, Martinez, D.R., Raut R, Markmann A, Bartelt L, Weiss S, Park Y, Weiskopf D, Tse LV, Margolis D, Sette A, Collins M, Schmitz J, Baric RS, de Silva AM. The Receptor Binding Domain of the Viral Spike Protein Is an Immunodominant and Highly Specific Target of Antibodies in SARS-CoV-2 Patients. Science Immunology. June 11, 2020. doi: 10.1126/sciimmunol.abc8413

17. Hou YJ ++, Okuda K ++, Edwards CE ++, Martinez, D.R.,++, Asakura T, Dinnon KH III, Kato T, Lee RE, Yount B, Mascenik TM, Chen G, Olivier KN, Ghio A, Tse LV, Leist SR, Gralinski LE, Schäfer A, Dang H, Gilmore R, Nakano S, Sun L, Fulcher ML, Livraghi-Butrico A, Nicely NI, Cameron M, Cameron C, Kelvin DJ, de Silva A, Margolis DM, Markmann A, Bartelt L, Zumwalt R, Martinez FJ, Salvatore SP, Borczuk A, Tata PR, Sontake V, Kimple A, Jaspers I, O’Neal WK, Randell S, Boucher RC, Baric RS. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. May 26, 2020. DOI:https://doi.org/10.1016/j.cell.2020.05.042 ++ Co-first author

16. Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez, D.R., Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, Estes JD, Andersen H, Lewis MG, Barouch DH. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. May 20, 2020. doi: 10.1126/science.abc4776.

15. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Nkolola JP, Liu J, Li Z, Chandrashekar A, Martinez, D.R., Loos C, Atyeo C, Fischinger S, Burke JS, Slein MD, Chen Y, Zuiani A, N Lelis FJ, Travers M, Habibi S, Pessaint L, Van Ry A, Blade K, Brown R, Cook A, Finneyfrock B, Dodson A, Teow E, Velasco J, Zahn R, Wegmann F, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kirilova M, Kordana N, Lin Z, Maxfield LF, Nampanya F, Nityanandam R, Ventura JD, Wan H, Cai Y, Chen B, Schmidt AG, Wesemann DR, Baric RS, Alter G, Andersen H, Lewis MG, Barouch DH. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. May 20, 2020. doi: 10.1126/science.abc6284.

14. Young E, Carnahan RH, Andrade DV, Kose N, Nargi RS, Fritch EJ, Munt JE, Doyle MP, White L, Baric TJ, Stoops M, DeSilva A, Tse LV, Martinez, D.R., Zhu D, Metz S, Wong MP, Espinosa DA, Montoya M, Biering SB, Sukulpolvi-Petty S, Kuan G, Balmaseda A, Diamond MS, Harris E, Crowe JE Jr, Baric RS. Identification of Dengue Virus Serotype 3 Specific Antigenic Sites Targeted by Neutralizing Human Antibodies. Cell Host and Microbe. May 13, 2020. doi: 10.1016/j.chom.2020.04.007.

Research publications from Ph.D. studies:

13. Tu J, Kumar A, Giorgi E, Eudailey J, LaBranche C, Martinez D.R., Fouda G, Moreau Y, Thomas A, Montefiori D, Gao F, Sagar M, Permar S.R., Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses. Journal of Virology. May 10, 2022. DOI: 10.1128/jvi.00231-22

12. Marichannegowda MH, Mengual M, Kumar A, Giorgi E, Tu J, Martinez D.R., Romero-Severson E, Li X, Feng L, Permar S, Gao F. Different evolutionary pathways of HIV-1 between fetus and mother perinatal transmission pairs indicate unique immune selection in fetuses. Cell Reports Medicine. July 16, 2021. DOI: 10.1016/j.xcrm.2021.100315

11. Kumar A, Giorgi E, Tu J, Martinez DR., Eudailey J, Mengual M, Marichannegowda M, Van Dyke R, Gao F, Permar SR., Mutations that confer resistance to broadly neutralizing antibodies define HIV-1 variants of transmitting mothers from that of non-transmitting mothers. PLoS Pathogens. April 2, 2021. doi: 10.1371/journal.ppat.1009478.

10. Post AL, Li SH, Berry M, Itell H, Martinez, D.R., Xie G, Permar SR, Swamy GK, Fouda GG. Efficiency of Placental Transfer of Vaccine-Elicited Antibodies Relative to Prenatal Tdap Vaccination Status. Vaccine. May 29, 2020. doi: 10.1016/j.vaccine.2020.05.036

9. Martinez, D.R. ++, Tu J ++, Kumar A, Mangold J, Mangan R, Goswami R, Giorgi EE, Chen J, Mengual M, Douglas AO, Heimsath H, Saunders KO, Nicely NI, Eudailey J, Hernandez G, Morgan-Asiedu PK, Wiehe K, Haynes BF, Moody MA, LaBrance C, Montefiori DC, Gao F, and Permar SR. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. mBio. March 10, 2020. Doi: 10.1128/mBio.00176-20 ++ Co-first author

8. Martinez, D.R., Fong, Y., Li, S. H., Yang, F., Jennewein, M., Weiner, J. A., Harrell, E. A., Mangold, J. F., Goswami, R., Seage, G., Alter, G., Ackerman, M. E., Peng, X., Fouda, G. G., and Permar, R. S. (2019). Fc Characteristics Mediate Selective Placental Transfer of IgG in HIV-Infected Women. Cell. June 27, 2019. https://doi.org/10.1016/j.cell.2019.05.046

7. Kumar A, Powers CE, Eudailey J, Giorgi E, Martinez, D.R., Douglas A, Stamper L, Fouda GG, McGuire E, Gao F, Permar SR. Infant Transmitted/Founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma. April 19, 2018. PLoS Pathogens. doi.org/10.1371/journal.ppat.1006944

6. Nguyen QQ*++, Martinez, D.R. ++, Jonathon E. Himes, Whitney Edwards, Qifeng Han, Amit Kumar, Nathan Nicely, Xiaoying Shen, Justin Pollara, and Sallie R. Permar. Predominant linear variable loop 2-specific and gp120-specific plasma IgG responses in acutely SIV-infected African Green monkeys. Retrovirology. March 9, 2018;15(1):24. doi: 10.1186/s12977-018-0406-5. ++ Co-first author

5. Perez, LG, Martinez, D.R., decamp AC, Pinter A, Berman PW, Donald Francis, Sinangil F, Lee C, Greene K, Gao H, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Robert O’Connell RJ, Robb ML, Michael NL, Kim JH, Gilbert P, Montefiori DC. V1V2-Specific Complement Activating Serum IgG as a Correlate of Reduced HIV-1 Infection Risk in RV144. PLoS ONE. July 5, 2017;12(7):e0180720. doi: 10.1371/journal.pone.0180720. eCollection 2017.

4. Martinez, D.R., Vandergrift N, Douglas AO, McGuire E, Bainbridge J, Nicely N, Montefiori DC, Tomaras GD, Fouda GF, Permar SR. Maternal binding and neutralizing IgG responses targeting the C terminal region of the V3 loop are predictive of reduced peripartum HIV-1 transmission risk. Journal of Virology. April 13, 2017. pii: JVI.02422-16. doi: 10.1128/JVI.02422-16.

3. Zhang R, Martinez, D.R., Nguyen QQ, Pollara J, Arifin T, Stolarchuk C, Foulger A, Amos JD, Parks R, Himes J, Wang M, Edwards RW, Trama AM, Vandergrift N, Colvin L, Dewar K, Juretic N, Wasserscheid J, Haynes BF, Ferrari G, Liao HX, Permar SR. Envelope-specific B-cell populations in African green monkeys chronically infected with simian immunodeficiency virus. Nature Communications. July 6, 2016. doi: 10.1038/ncomms12131.

2. Amos JD, Himes JE, Armand L, Gurley TC, Martinez, D.R., Colvin L, Beck K, Overman RG, Liao HX, Moody MA, Permar SR. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys. Journal of Virology. September 15, 2015;89 (18):9485-98. doi: 10.1128/JVI.01564-15.

1. Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, Jaeger FH, Pollara J, Martelli A, Liebl BE, Lloyd K, Yates NL, Overman RG, Shen X, Whitaker K, Chen H, Pritchett J, Solomon E, Friberg E, Marshall DJ, Whitesides JF, Gurley TC, Von Holle T, Martinez, D.R., Cai F, Kumar A, Xia SM, Lu X, Louzao R, Wilkes S, Datta S, Sarzotti-Kelsoe M, Liao HX, Ferrari G, Alam SM, Montefiori DC, Denny TN, Moody MA, Tomaras GD, Gao F, Haynes BF. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission. Journal of Clinical Investigation. July 1, 2015;125 (7):2702-6. doi: 10.1172/JCI81593.